While Wall Street analysts remain cautious on Hims & Hers Health (HIMS), TipRanks’ A.I. Stock Analysis tool shows strong ...

Shedeur Sanders' NFL debut had plenty of anticipation, but it wasn't just his throws that caught fans' attention. The Cleveland Browns rookie quarterback found himself in a moment ...

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.

In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while ...

HIMS records subscriber surge and revenue growth in second-quarter 2025, but rising costs strain gross margins.

Morgan Stanley reports that third party data point to a 20% year-over-year decline for Hims & Hers app downloads in the month of July and that ...

Current health news highlights include UK investor backing in Assura's acquisition by PHP, Novo Nordisk's legal affairs over Wegovy drug sales, and Apollo Hospitals' increased AI investments. The CDC ...

May 31, 2021. China's vast manufacturing sector grew at the fastest pace in eight months in May, blowing past e ...

Through a trust, Dudum sold about $33.4 million worth of his company's stock on Thursday, according to a filing with the Securities and Exchange Commission put out after Monday's closing bell. The CEO ...

Telehealth company Hims & Hers Health (NYSE:HIMS) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 72.6% year on year to $544.8 million. On the other hand, the company expects ...

Hims & Hers Health’s second quarter results were met with a significant negative market reaction, as sales growth lagged Wall Street’s expectations despite a strong rise in non-GAAP profitability.

In Q2 2025, Hims & Hers reported adjusted earnings of $0.17 per share, topping estimates of $0.15. Revenue rose 73% year-over ...